Pathophysiology of ovarian hyperstimulation syndrome and strategies for its prevention and treatment

References

• Smits G, Olatunbosun O, Delbaere A, Pierson R, Vassart G, Costagliola S. Ovarian hyperstimulation syndrome due to a mutation in the follicle-stimulating hormone receptor. N. Engl. J. Med.349(8), 760–766 (2003).
   PubMed Web of Science ®Google Scholar
• Vasseur C, Rodien P, Beau I et al. A chorionic gonadotropin-sensitive mutation in the follicle-stimulating hormone receptor as a cause of familial gestational spontaneous ovarian hyperstimulation syndrome. N. Engl. J. Med.349(8), 753–759 (2003).
   PubMed Web of Science ®Google Scholar
• Arora R, Merhi ZO, Khulpateea N, Roth D, Minkoff H. Ovarian hyperstimulation syndrome after a molar pregnancy evacuation. Fertil. Steril.90(4), e1195–e1197 (2008).
   Google Scholar
• Ludwig M, Gembruch U, Bauer O, Diedrich K. Ovarian hyperstimulation syndrome (OHSS) in a spontaneous pregnancy with fetal and placental triploidy: information about the general pathophysiology of OHSS. Hum. Reprod.13(8), 2082–2087 (1998).
   PubMed Web of Science ®Google Scholar
• Nappi RG, Di Naro E, D’Aries AP, Nappi L. Natural pregnancy in hypothyroid woman complicated by spontaneous ovarian hyperstimulation syndrome. Am. J. Obstet. Gynecol.178(3), 610–611 (1998).
   PubMed Web of Science ®Google Scholar
• Check JH, Choe JK, Nazari A. Hyperreactio luteinalis despite the absence of a corpus luteum and suppressed serum follicle stimulating concentrations in a triplet pregnancy. Hum. Reprod.15(5), 1043–1045 (2000).
   PubMedGoogle Scholar
• Suzuki S. Comparison between spontaneous ovarian hyperstimulation syndrome and hyperreactio luteinalis. Arch. Gynecol. Obstet.269(3), 227–229 (2004).
   PubMedGoogle Scholar
• Aboulghar MA, Mansour RT. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Hum. Reprod. Update9(3), 275–289 (2003).
   PubMed Web of Science ®Google Scholar
• McClure N, Healy DL, Rogers PA et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet344(8917), 235–236 (1994).
   PubMed Web of Science ®Google Scholar
• Goldsman MP, Pedram A, Dominguez CE, Ciuffardi I, Levin E, Asch RH. Increased capillary permeability induced by human follicular fluid: a hypothesis for an ovarian origin of the hyperstimulation syndrome. Fertil. Steril.63(2), 268–272 (1995).
   PubMed Web of Science ®Google Scholar
• Soares SR, Gomez R, Simon C, Garcia-Velasco JA, Pellicer A. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum. Reprod. Update14(4), 321–333 (2008).
   PubMed Web of Science ®Google Scholar
• Albert C, Garrido N, Mercader A et al. The role of endothelial cells in the pathogenesis of ovarian hyperstimulation syndrome. Mol. Hum. Reprod.8(5), 409–418 (2002).
   PubMed Web of Science ®Google Scholar
• de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science255(5047), 989–991 (1992).
   PubMed Web of Science ®Google Scholar
• Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol. Chem.269(43), 26988–26995 (1994).
   PubMed Web of Science ®Google Scholar
• Pajusola K, Aprelikova O, Korhonen J et al. FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines. Cancer Res.52(20), 5738–5743 (1992).
   PubMed Web of Science ®Google Scholar
• Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc. Res.65(3), 550–563 (2005).
   PubMed Web of Science ®Google Scholar
• Gomez R, Simon C, Remohi J, Pellicer A. Administration of moderate and high doses of gonadotropins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability. Biol. Reprod.68(6), 2164–2171 (2003).
   PubMed Web of Science ®Google Scholar
• Gomez R, Gonzalez M, Simon C, Remohi J, Pellicer A. Tyroxine hydroxylase (TH) down regulation in hyperstimulated ovaries reveals the dopamine agonist bromocriptine (Br2) as an effective and specific method to block increased vascular permeability (VP) in OHSS. Fertil. Steril.80(Suppl. 3), 43–44 (2003).
   PubMedGoogle Scholar
• Hornig C, Barleon B, Ahmad S, Vuorela P, Ahmed A, Weich HA. Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids. Lab. Invest.80(4), 443–454 (2000).
   PubMed Web of Science ®Google Scholar
• He Y, Smith SK, Day KA, Clark DE, Licence DR, Charnock-Jones DS. Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. Mol. Endocrinol.13(4), 537–545 (1999).
   PubMed Web of Science ®Google Scholar
• Wang D, Donner DB, Warren RS. Homeostatic modulation of cell surface KDR and Flt1 expression and expression of the vascular endothelial cell growth factor (VEGF) receptor mRNAs by VEGF. J. Biol. Chem.275(21), 15905–15911 (2000).
   PubMedGoogle Scholar
• Roberts WG, Palade GE. Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res.57(4), 765–772 (1997).
   PubMed Web of Science ®Google Scholar
• Villasante A, Pacheco A, Ruiz A, Pellicer A, Garcia-Velasco JA. Vascular endothelial cadherin regulates vascular permeability: implications for ovarian hyperstimulation syndrome. J. Clin. Endocrinol. Metab.92(1), 314–321 (2007).
   PubMed Web of Science ®Google Scholar
• Wang TH, Horng SG, Chang CL et al. Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor. J. Clin. Endocrinol. Metab.87(7), 3300–3308 (2002).
   PubMed Web of Science ®Google Scholar
• Pellicer A, Albert C, Mercader A, Bonilla-Musoles F, Remohi J, Simon C. The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1β, interleukin-6, and vascular endothelial growth factor. Fertil. Steril.71(3), 482–489 (1999).
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Konishi I, Tsuruta Y et al. Expression of vascular endothelial growth factor (VEGF) during folliculogenesis and corpus luteum formation in the human ovary. Gynecol. Endocrinol.11(6), 371–381 (1997).
   PubMed Web of Science ®Google Scholar
• Kamat BR, Brown LF, Manseau EJ, Senger DR, Dvorak HF. Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development. Am. J. Pathol.146(1), 157–165 (1995).
   PubMed Web of Science ®Google Scholar
• Gomez R, Simon C, Remohi J, Pellicer A. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. Endocrinology143(11), 4339–4348 (2002).
   PubMed Web of Science ®Google Scholar
• Pau E, Alonso-Muriel I, Gomez R et al. Plasma levels of soluble vascular endothelial growth factor receptor-1 may determine the onset of early and late ovarian hyperstimulation syndrome. Hum. Reprod.21(6), 1453–1460 (2006).
   PubMed Web of Science ®Google Scholar
• Itskovitz J, Sealey JE. Ovarian prorenin–renin–angiotensin system. Obstet. Gynecol. Surv.42(9), 545–551 (1987).
   PubMedGoogle Scholar
• Lightman A, Tarlatzis BC, Rzasa PJ et al. The ovarian renin–angiotensin system: renin-like activity and angiotensin II/III immunoreactivity in gonadotropin-stimulated and unstimulated human follicular fluid. Am. J. Obstet. Gynecol.156(4), 808–816 (1987).
   PubMed Web of Science ®Google Scholar
• Blankestijn PJ, Derkx FH, Van Geelen JA, De Jong FH, Schalekamp MA. Increase in plasma prorenin during the menstrual cycle of a bilaterally nephrectomized woman. Br. J. Obstet. Gynaecol.97(11), 1038–1042 (1990).
   PubMedGoogle Scholar
• Glorioso N, Atlas SA, Laragh JH, Jewelewicz R, Sealey JE. Prorenin in high concentrations in human ovarian follicular fluid. Science233(4771), 1422–1424 (1986).
   PubMed Web of Science ®Google Scholar
• Morris RS, Paulson RJ. Ovarian derived prorenin–angiotensin cascade in human reproduction. Fertil. Steril.62(6), 1105–1114 (1994).
   PubMed Web of Science ®Google Scholar
• Huang W, Wu YL, Zhong J, Jiang FX, Tian XL, Yu LF. Angiotensin II type 1 receptor antagonist suppress angiogenesis and growth of gastric cancer xenografts. Dig. Dis. Sci.53(5), 1206–1210 (2008).
   PubMedGoogle Scholar
• Shi RZ, Wang JC, Huang SH, Wang XJ, Li QP. Angiotensin II induces vascular endothelial growth factor synthesis in mesenchymal stem cells. Exp. Cell Res.315(1), 10–15 (2009).
   PubMed Web of Science ®Google Scholar
• Anandanadesan R, Gong Q, Chipitsyna G, Witkiewicz A, Yeo CJ, Arafat HA. Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1/2 signaling. J. Gastrointest. Surg.12(1), 57–66 (2008).
   PubMedGoogle Scholar
• Sataranatarajan K, Lee MJ, Mariappan MM, Feliers D. PKCd regulates the stimulation of vascular endothelial factor mRNA translation by angiotensin II through hnRNP K. Cell. Signal.20(5), 969–977 (2008).
   PubMedGoogle Scholar
• Walter A, Etienne-Selloum N, Sarr M, Kane MO, Beretz A, Schini-Kerth VB. Angiotensin II induces the vascular expression of VEGF and MMP-2 in vivo: preventive effect of red wine polyphenols. J. Vasc. Res.45(5), 386–394 (2008).
   PubMed Web of Science ®Google Scholar
• Herr D, Rodewald M, Fraser HM et al. Regulation of endothelial proliferation by the renin–angiotensin system in human umbilical vein endothelial cells. Reproduction136(1), 125–130 (2008).
   PubMedGoogle Scholar
• Ohnuma Y, Toda M, Fujita M et al. Blockade of an angiotensin type I receptor enhances effects of radiation on tumor growth and tumor-associated angiogenesis by reducing vascular endothelial growth factor expression. Biomed. Pharmacother.63(2), 136–145 (2007).
   PubMedGoogle Scholar
• Fukumoto M, Takai S, Ishizaki E et al. Involvement of angiotensin II-dependent vascular endothelial growth factor gene expression via NADPH oxidase in the retina in a Type 2 diabetic rat model. Curr. Eye Res.33(10), 885–891 (2008).
   PubMed Web of Science ®Google Scholar
• Delbaere A, Bergmann PJ, Gervy-Decoster C, Camus M, de Maertelaer V, Englert Y. Prorenin and active renin concentrations in plasma and ascites during severe ovarian hyperstimulation syndrome. Hum. Reprod.12(2), 236–240 (1997).
   PubMed Web of Science ®Google Scholar
• Delvigne A, Rozenberg S. Preventive attitude of physicians to avoid OHSS in IVF patients. Hum. Reprod.16(12), 2491–2495 (2001).
   PubMed Web of Science ®Google Scholar
• The Practice Committee of the American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil. Steril.90(5 Suppl.), S188–S193 (2008).
   PubMed Web of Science ®Google Scholar
• Enskog A, Henriksson M, Unander M, Nilsson L, Brannstrom M. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil. Steril.71(5), 808–814 (1999).
   PubMed Web of Science ®Google Scholar
• Delvigne A, Demoulin A, Smitz J et al. The ovarian hyperstimulation syndrome in in vitro fertilization: a Belgian multicentric study. I. Clinical and biological features. Hum. Reprod.8(9), 1353–1360 (1993).
   PubMed Web of Science ®Google Scholar
• Braat D, Bernardus R, Gerris J. Anonymous reports of lethal cases of ovarian hyperstimulation syndrome. In: Ovarian Hyperstimulation Syndrome. Gerris J, Delvigne A, Olivennes F (Eds). Informa Healthcare, Oxon, UK, 59–70 (2006).
   Google Scholar
• MacDougall MJ, Tan SL, Balen A, Jacobs HS. A controlled study comparing patients with and without polycystic ovaries undergoing in vitro fertilization. Hum. Reprod.8(2), 233–237 (1993).
   PubMed Web of Science ®Google Scholar
• van Dop P. Epidemiology and primary risk factors for ovarian hyperstimulation syndrome. In: Ovarian Hyperstimulation syndrome. Gerris J, Delvigne A, Olivennes F (Eds). Informa Healthcare, Oxon, UK, 7–11 (2006).
   Google Scholar
• Nakhuda GS, Chu MC, Wang JG, Sauer MV, Lobo RA. Elevated serum mullerian-inhibiting substance may be a marker for ovarian hyperstimulation syndrome in normal women undergoing in vitro fertilization. Fertil. Steril.85(5), 1541–1543 (2006).
   PubMed Web of Science ®Google Scholar
• Lee TH, Liu CH, Huang CC et al. Serum anti-Mullerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum. Reprod.23(1), 160–167 (2008).
   PubMed Web of Science ®Google Scholar
• Lussiana C, Guani B, Mari C, Restagno G, Massobrio M, Revelli A. Mutations and polymorphisms of the FSH receptor (FSHR) gene: clinical implications in female fecundity and molecular biology of FSHR protein and gene. Obstet. Gynecol. Surv.63(12), 785–795 (2008).
   PubMed Web of Science ®Google Scholar
• Meduri G, Bachelot A, Cocca MP et al. Molecular pathology of the FSH receptor: new insights into FSH physiology. Mol. Cell. Endocrinol.282(1–2), 130–142 (2008).
   PubMed Web of Science ®Google Scholar
• Achrekar SK, Modi DN, Desai SK, Mangoli VS, Mangoli RV, Mahale SD. Follicle-stimulating hormone receptor polymorphism (Thr307Ala) is associated with variable ovarian response and ovarian hyperstimulation syndrome in Indian women. Fertil. Steril.91(2), 432–439 (2009).
   PubMed Web of Science ®Google Scholar
• Binder H, Dittrich R, Hager I et al. Association of FSH receptor and CYP19A1 gene variations with sterility and ovarian hyperstimulation syndrome. Reproduction135(1), 107–116 (2008).
   PubMed Web of Science ®Google Scholar
• Daelemans C, Smits G, de Maertelaer V et al. Prediction of severity of symptoms in iatrogenic ovarian hyperstimulation syndrome by follicle-stimulating hormone receptor Ser680Asn polymorphism. J. Clin. Endocrinol. Metab.89(12), 6310–6315 (2004).
   PubMed Web of Science ®Google Scholar
• d’Alva CB, Serafini P, Motta E, Kohek MB, Latronico AC, Mendonca BB. Absence of follicle-stimulating hormone receptor activating mutations in women with iatrogenic ovarian hyperstimulation syndrome. Fertil. Steril.83(6), 1695–1699 (2005).
   PubMed Web of Science ®Google Scholar
• Kerkela E, Skottman H, Friden B, Bjuresten K, Kere J, Hovatta O. Exclusion of coding-region mutations in luteinizing hormone and follicle-stimulating hormone receptor genes as the cause of ovarian hyperstimulation syndrome. Fertil. Steril.87(3), 603–606 (2007).
   PubMed Web of Science ®Google Scholar
• Delvigne A, Rozenberg S. Systematic review of data concerning etiopathology of ovarian hyperstimulation syndrome. Int. J. Fertil. Womens Med.47(5), 211–226 (2002).
   PubMedGoogle Scholar
• Asch RH, Li HP, Balmaceda JP, Weckstein LN, Stone SC. Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups. Hum. Reprod.6(10), 1395–1399 (1991).
   PubMed Web of Science ®Google Scholar
• Morris RS, Paulson RJ, Sauer MV, Lobo RA. Predictive value of serum oestradiol concentrations and oocyte number in severe ovarian hyperstimulation syndrome. Hum. Reprod.10(4), 811–814 (1995).
   PubMed Web of Science ®Google Scholar
• Mathur RS, Akande AV, Keay SD, Hunt LP, Jenkins JM. Distinction between early and late ovarian hyperstimulation syndrome. Fertil. Steril.73(5), 901–907 (2000).
   PubMed Web of Science ®Google Scholar
• Pellicer A, Miro F, Sampaio M, Gomez E, Bonilla-Musoles FM. In vitro fertilization as a diagnostic and therapeutic tool in a patient with partial 17,20-desmolase deficiency. Fertil. Steril.55(5), 970–975 (1991).
   PubMedGoogle Scholar
• Schenker JG. Prevention and treatment of ovarian hyperstimulation. Hum. Reprod.8(5), 653–659 (1993).
   PubMedGoogle Scholar
• Blankstein J, Shalev J, Saadon T et al. Ovarian hyperstimulation syndrome: prediction by number and size of preovulatory ovarian follicles. Fertil. Steril.47(4), 597–602 (1987).
   PubMed Web of Science ®Google Scholar
• Tal J, Paz B, Samberg I, Lazarov N, Sharf M. Ultrasonographic and clinical correlates of menotropin versus sequential clomiphene citrate: menotropin therapy for induction of ovulation. Fertil. Steril.44(3), 342–349 (1985).
   PubMedGoogle Scholar
• Costello MF, Chapman M, Conway U. A systematic review and meta-analysis of randomized controlled trials on metformin co-administration during gonadotrophin ovulation induction or IVF in women with polycystic ovary syndrome. Hum. Reprod.21(6), 1387–1399 (2006).
   PubMed Web of Science ®Google Scholar
• Moll E, van der Veen F, van Wely M. The role of metformin in polycystic ovary syndrome: a systematic review. Hum. Reprod. Update13(6), 527–537 (2007).
   PubMed Web of Science ®Google Scholar
• Doronzo G, Russo I, Mattiello L, Anfossi G, Bosia A, Trovati M. Insulin activates vascular endothelial growth factor in vascular smooth muscle cells: influence of nitric oxide and of insulin resistance. Eur. J. Clin. Invest.34(10), 664–673 (2004).
   PubMed Web of Science ®Google Scholar
• Rimington MR, Walker SM, Shaw RW. The use of laparoscopic ovarian electrocautery in preventing cancellation of in vitro fertilization treatment cycles due to risk of ovarian hyperstimulation syndrome in women with polycystic ovaries. Hum. Reprod.12(7), 1443–1447 (1997).
   PubMed Web of Science ®Google Scholar
• Tozer AJ, Al-Shawaf T, Zosmer A et al. Does laparoscopic ovarian diathermy affect the outcome of IVF-embryo transfer in women with polycystic ovarian syndrome? A retrospective comparative study. Hum. Reprod.16(1), 91–95 (2001).
   PubMed Web of Science ®Google Scholar
• Tan SL, Child TJ, Cheung AP et al. A randomized, double-blind, multicenter study comparing a starting dose of 100 IU or 200 IU of recombinant follicle stimulating hormone (Puregon) in women undergoing controlled ovarian hyperstimulation for IVF treatment. J. Assist. Reprod. Genet.22(2), 81–88 (2005).
   PubMedGoogle Scholar
• Marci R, Senn A, Dessole S et al. A low-dose stimulation protocol using highly purified follicle-stimulating hormone can lead to high pregnancy rates in in vitro fertilization patients with polycystic ovaries who are at risk of a high ovarian response to gonadotropins. Fertil. Steril.75(6), 1131–1135 (2001).
   PubMed Web of Science ®Google Scholar
• Daya S. Updated meta-analysis of recombinant follicle-stimulating hormone (FSH) versus urinary FSH for ovarian stimulation in assisted reproduction. Fertil. Steril.77(4), 711–714 (2002).
   PubMed Web of Science ®Google Scholar
• Van Wely M, Westergaard LG, Bossuyt PM, Van der Veen F. Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. Cochrane Database Syst. Rev.1, CD003973 (2003).
   Google Scholar
• Coomarasamy A, Afnan M, Cheema D, van der Veen F, Bossuyt PM, van Wely M. Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. Hum. Reprod.23(2), 310–315 (2008).
   PubMed Web of Science ®Google Scholar
• Nugent D, Vandekerckhove P, Hughes E, Arnot M, Lilford R. Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst. Rev.4, CD000410 (2000).
   Google Scholar
• Bayram N, van Wely M, van Der Veen F. Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst. Rev.2, CD002121 (2001).
   Google Scholar
• Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum. Reprod. Update8(6), 559–577 (2002).
   PubMed Web of Science ®Google Scholar
• Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst. Rev.3, CD001750 (2006).
   Google Scholar
• Kolibianakis EM, Collins J, Tarlatzis BC, Devroey P, Diedrich K, Griesinger G. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Hum. Reprod. Update12(6), 651–671 (2006).
   PubMed Web of Science ®Google Scholar
• Albano C, Felberbaum RE, Smitz J et al. Ovarian stimulation with HMG: results of a prospective randomized Phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Hum. Reprod.15(3), 526–531 (2000).
   PubMed Web of Science ®Google Scholar
• Badrawy A, Al-Inany HG, Hussein M, Zaki S, Ramzy AM. Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis. Middle East Fertil. Soc. J.10(1), 49–54 (2005).
   Google Scholar
• Barmat LI, Chantilis SJ, Hurst BS, Dickey RP. A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization. Fertil. Steril.83(2), 321–330 (2005).
   PubMed Web of Science ®Google Scholar
• Causio F, Sarcina E, Leonetti T. GnRH agonist versus GnRH antagonist in an IVF program: luteal phase hormonal characteristics. Hum. Reprod.19(Suppl.), i103 (2004).
   Google Scholar
• Cheung LP, Lam PM, Lok IH et al. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial. Hum. Reprod.20(3), 616–621 (2005).
   PubMed Web of Science ®Google Scholar
• Franco JJ, Baruffi R, Petersen C, Mauri A, Felipe V, Contart P. Comparison of ovarian stimulation with recombinant FSH after 2nd phase protocols with GnRH analogs (I - estradiol + ganirelix versus II -nafarelin). Comparacao da stimulacao ovariana comFSH recombinante apos protocolo de 2A fase com analogos do GNRH (I - estradiol + ganirelix versus II - nafarelin)]. J. Brasil. Reprod. Assist.7(1), 26–32 (2003).
   Google Scholar
• Friedler S, Gilboa S, Schachter M et al. Luteal phase characteristics following GnRH antagonist or agonist treatment: a randomized comparative study. Hum. Reprod.18(Suppl.), xviii 26 (2003).
   Google Scholar
• Hohmann FP, Macklon NS, Fauser BC. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. J. Clin. Endocrinol. Metab.88(1), 166–173 (2003).
   PubMed Web of Science ®Google Scholar
• Kyono K, Nakajo Y, Sasaki S, Kumagai S, Suzuki S. A prospective randomized study of three different controlled ovarian hyperstimulation (COH) protocols. Fertil. Steril.84(Suppl. 1), S299 (2005).
   Google Scholar
• Lee TH, Wu MY, Chen HF, Chen MJ, Ho HN, Yang YS. Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration. Fertil. Steril.83(6), 1700–1707 (2005).
   PubMedGoogle Scholar
• Loutradis D, Stefanidis K, Drakakis P, Milingos S, Antsaklis A, Michalas S. A modified gonadotropin-releasing hormone (GnRH) antagonist protocol failed to increase clinical pregnancy rates in comparison with the long GnRH protocol. Fertil. Steril.82(5), 1446–1448 (2004).
   PubMed Web of Science ®Google Scholar
• Marci R, Caserta D, Dolo V, Tatone C, Pavan A, Moscarini M. GnRH antagonist in IVF poor-responder patients: results of a randomized trial. Reprod. Biomed. Online11(2), 189–193 (2005).
   PubMed Web of Science ®Google Scholar
• Olivennes F, Belaisch-Allart J, Emperaire JC et al. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil. Steril.73(2), 314–320 (2000).
   PubMed Web of Science ®Google Scholar
• Rombauts L, Healy D, Norman RJ. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist-treated patients. Hum. Reprod.21(1), 95–103 (2006).
   PubMed Web of Science ®Google Scholar
• Zikopoulos K, Kaponis A, Adonakis G et al. A prospective randomized study comparing gonadotropin-releasing hormone agonists or gonadotropin-releasing hormone antagonists in couples with unexplained infertility and/or mild oligozoospermia. Fertil. Steril.83(5), 1354–1362 (2005).
   PubMedGoogle Scholar
• Griesinger G, Diedrich K, Tarlatzis BC, Kolibianakis EM. GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. Reprod. Biomed. Online13(5), 628–638 (2006).
   PubMed Web of Science ®Google Scholar
• El-Sheikh MM, Hussein M, Sheikh AA, Fouad S, El-Sheikh R, Al-Hasani S. Limited ovarian stimulation results in the recovery of mature oocytes in polycystic ovarian disease patients: a preliminary report. Eur. J. Obstet. Gynecol. Reprod. Biol.83(1), 81–83 (1999).
   PubMedGoogle Scholar
• El-Sheikh MM, Hussein M, Fouad S, El-Sheikh R, Bauer O, Al-Hasani S. Limited ovarian stimulation (LOS), prevents the recurrence of severe forms of ovarian hyperstimulation syndrome in polycystic ovarian disease. Eur. J. Obstet. Gynecol. Reprod. Biol.94(2), 245–249 (2001).
   PubMedGoogle Scholar
• Lim KS, Yoon SH, Lim JH. IVM as an alternative for over responders. In: In VitroMaturation of Human Oocytes. Basic Science to Clinical Application. Tan SL, Chian RC, Buckett WM (Eds). Informa Healthcare, Oxon, UK, 353–361 (2007).
   Google Scholar
• Lipitz S, Ben-Rafael Z, Bider D, Shalev J, Mashiach S. Quintuplet pregnancy and third degree ovarian hyperstimulation despite withholding human chorionic gonadotrophin. Hum. Reprod.6(10), 1478–1479 (1991).
   PubMedGoogle Scholar
• The European Recombinant LH Study Group. Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study. J. Clin. Endocrinol. Metab.86(6), 2607–2618 (2001).
   PubMed Web of Science ®Google Scholar
• Manau D, Fabregues F, Arroyo V, Jimenez W, Vanrell JA, Balasch J. Hemodynamic changes induced by urinary human chorionic gonadotropin and recombinant luteinizing hormone used for inducing final follicular maturation and luteinization. Fertil. Steril.78(6), 1261–1267 (2002).
   PubMed Web of Science ®Google Scholar
• Al-Inany H, Aboulghar MA, Mansour RT, Proctor M. Recombinant versus urinary gonadotrophins for triggering ovulation in assisted conception. Hum. Reprod.20(8), 2061–2073 (2005).
   PubMed Web of Science ®Google Scholar
• Delvigne A. Secondary prevention of threatening ovarian hyperstimulation syndrome. In: Ovarian Hyperstimulation Syndrome. Gerris J, Delvigne A, Olivennes F (Eds). Informa Healthcare, Oxon, UK, 217–238 (2006).
   Google Scholar
• Acevedo B, Gomez-Palomares JL, Ricciarelli E, Hernandez ER. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. Fertil. Steril.86(6), 1682–1687 (2006).
   PubMed Web of Science ®Google Scholar
• Kol S. Does ovulation triggering influence the risk for ovarian hyperstimulation syndrome? In: Ovarian Hyperstimulation Syndrome. Gerris J, Delvigne A, Olivennes F (Eds). Informa Healthcare, Oxon, UK, 203–216 (2006).
   Google Scholar
• Kol S, Solt I. GnRH agonist for triggering final oocyte maturation in patients at risk of ovarian hyperstimulation syndrome: still a controversy? J. Assist. Reprod. Genet.25(2–3), 63–66 (2008).
   PubMed Web of Science ®Google Scholar
• Itskovitz J, Boldes R, Levron J, Erlik Y, Kahana L, Brandes JM. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertil. Steril.56(2), 213–220 (1991).
   PubMed Web of Science ®Google Scholar
• Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil. Steril.89(1), 84–91 (2008).
   PubMed Web of Science ®Google Scholar
• Garcia-Velasco JA, Zuniga A, Pacheco A et al. Coasting acts through downregulation of VEGF gene expression and protein secretion. Hum. Reprod.19(7), 1530–1538 (2004).
   PubMedGoogle Scholar
• Mansour R, Aboulghar M, Serour G, Amin Y, Abou-Setta AM. Criteria of a successful coasting protocol for the prevention of severe ovarian hyperstimulation syndrome. Hum. Reprod.20(11), 3167–3172 (2005).
   PubMed Web of Science ®Google Scholar
• Ulug U, Bahceci M, Erden HF, Shalev E, Ben-Shlomo I. The significance of coasting duration during ovarian stimulation for conception in assisted fertilization cycles. Hum. Reprod.17(2), 310–313 (2002).
   PubMedGoogle Scholar
• Isaza V, Garcia-Velasco JA, Aragones M, Remohi J, Simon C, Pellicer A. Oocyte and embryo quality after coasting: the experience from oocyte donation. Hum. Reprod.17(7), 1777–1782 (2002).
   PubMed Web of Science ®Google Scholar
• Urman B, Pride SM, Yuen BH. Management of overstimulated gonadotrophin cycles with a controlled drift period. Hum. Reprod.7(2), 213–217 (1992).
   PubMedGoogle Scholar
• Sher G, Salem R, Feinman M, Dodge S, Zouves C, Knutzen V. Eliminating the risk of life-endangering complications following overstimulation with menotropin fertility agents: a report on women undergoing in vitro fertilization and embryo transfer. Obstet. Gynecol.81(6), 1009–1011 (1993).
   PubMed Web of Science ®Google Scholar
• Dhont M, Van der Straeten F, De Sutter P. Prevention of severe ovarian hyperstimulation by coasting. Fertil. Steril.70(5), 847–850 (1998).
   PubMed Web of Science ®Google Scholar
• Egbase PE, Sharhan MA, Grudzinskas JG. Early unilateral follicular aspiration compared with coasting for the prevention of severe ovarian hyperstimulation syndrome: a prospective randomized study. Hum. Reprod.14(6), 1421–1425 (1999).
   PubMed Web of Science ®Google Scholar
• Garcia-Velasco JA, Isaza V, Quea G, Pellicer A. Coasting for the prevention of ovarian hyperstimulation syndrome: much ado about nothing? Fertil. Steril.85(3), 547–554 (2006).
   PubMed Web of Science ®Google Scholar
• Mathur R, Kailasam C, Jenkins J. Review of the evidence base of strategies to prevent ovarian hyperstimulation syndrome. Hum. Fertil. (Camb.)10(2), 75–85 (2007).
   PubMedGoogle Scholar
• Ho Yuen B, Nguyen TA, Cheung AP, Leung PC. Clinical and endocrine response to the withdrawal of gonadotropin-releasing hormone agonists during prolonged coasting. Fertil. Steril. DOI: 10.1016/j.fertnstert.2008.06.039 (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Giles J, Requena A, Garcia-Velasco JA, Pacheco A, Pellicer J, Pellicer A. GnRH analogue for the prevention of ovarian hyperstimulation syndrome: a pilot study. Fertil. Steril.91(4), 1366–1369(2008).
   PubMedGoogle Scholar
• Lainas TG, Sfontouris IA, Zorzovilis IZ, Petsas GK, Lainas GT, Kolibianakis EM. Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist. Reprod. Biomed. Online15(4), 408–412 (2007).
   PubMed Web of Science ®Google Scholar
• Nikolettos N, Asimakopoulos B, Simopoulou M, al-Hasani S. GnRH agonist administration after embryo transfer, in long protocol stimulated cycles, prevents ovarian hyperstimulation syndrome. A report of five cases. In Vivo17(6), 655–658 (2003).
   PubMedGoogle Scholar
• Endo T, Honnma H, Hayashi T et al. Continuation of GnRH agonist administration for 1 week, after hCG injection, prevents ovarian hyperstimulation syndrome following elective cryopreservation of all pronucleate embryos. Hum. Reprod.17(10), 2548–2551 (2002).
   PubMed Web of Science ®Google Scholar
• Wada I, Matson PL, Horne G, Buck P, Lieberman BA. Is continuation of a gonadotrophin-releasing hormone agonist (GnRHa) necessary for women at risk of developing the ovarian hyperstimulation syndrome? Hum. Reprod.7(8), 1090–1093 (1992).
   PubMedGoogle Scholar
• Farhi J, Ben-Haroush A, Lande Y, Sapir O, Pinkas H, Fisch B. In vitro fertilization cycle outcome after coasting in gonadotropin-releasing hormone (GnRH) agonist versus GnRH antagonist protocols. Fertil. Steril.91(2), 377–382 (2008).
   PubMedGoogle Scholar
• Bowling KM, Huang Z, Xu D et al. Direct binding of GTP cyclohydrolase and tyrosine hydroxylase: regulatory interactions between key enzymes in dopamine biosynthesis. J. Biol. Chem.283(46), 31449–31459 (2008).
   PubMedGoogle Scholar
• Basu S, Nagy JA, Pal S et al. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat. Med.7(5), 569–574 (2001).
   PubMed Web of Science ®Google Scholar
• Sarkar C, Chakroborty D, Mitra RB, Banerjee S, Dasgupta PS, Basu S. Dopamine in vivo inhibits VEGF-induced phosphorylation of VEGFR-2, MAPK, and focal adhesion kinase in endothelial cells. Am. J. Physiol. Heart Circ. Physiol.287(4), H1554–H1560 (2004).
   PubMed Web of Science ®Google Scholar
• Quinn TP, Peters KG, De Vries C, Ferrara N, Williams LT. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc. Natl Acad. Sci. USA90(16), 7533–7537 (1993).
   PubMed Web of Science ®Google Scholar
• Gomez R, Gonzalez-Izquierdo M, Zimmermann RC et al. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology147(11), 5400–5411 (2006).
   PubMed Web of Science ®Google Scholar
• Alvarez C, Marti-Bonmati L, Novella-Maestre E et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J. Clin. Endocrinol. Metab.92(8), 2931–2937 (2007).
   PubMed Web of Science ®Google Scholar
• Alvarez C, Alonso-Muriel I, Garcia G et al. Implantation is apparently unaffected by the dopamine agonist cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Hum. Reprod.22(12), 3210–3214 (2007).
   PubMed Web of Science ®Google Scholar
• Carizza C, Abdelmassih V, Abdelmassih S et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reprod. Biomed. Online17(6), 751–755 (2008).
   PubMed Web of Science ®Google Scholar
• Ando H, Furugori K, Shibata D, Harata T, Murata Y, Mizutani S. Dual renin–angiotensin blockade therapy in patients at high risk of early ovarian hyperstimulation syndrome receiving IVF and elective embryo cryopreservation: a case series. Hum. Reprod.18(6), 1219–1222 (2003).
   PubMed Web of Science ®Google Scholar
• Ata B, Yakin K, Alatas C, Urman B. Dual renin–angiotensin blockage and total embryo cryopreservation is not a risk-free strategy in patients at high risk for ovarian hyperstimulation syndrome. Fertil. Steril.90(3), 531–536 (2008).
   PubMed Web of Science ®Google Scholar
• Aboulghar M, Evers JH, Al-Inany H. Intravenous albumin for preventing severe ovarian hyperstimulation syndrome: a Cochrane review. Hum. Reprod.17(12), 3027–3032 (2002).
   PubMed Web of Science ®Google Scholar
• Bellver J, Munoz EA, Ballesteros A et al. Intravenous albumin does not prevent moderate–severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study. Hum. Reprod.18(11), 2283–2288 (2003).
   PubMed Web of Science ®Google Scholar
• Isikoglu M, Berkkanoglu M, Senturk Z, Ozgur K. Human albumin does not prevent ovarian hyperstimulation syndrome in assisted reproductive technology program: a prospective randomized placebo-controlled double blind study. Fertil. Steril.88(4), 982–985 (2007).
   PubMedGoogle Scholar
• Gokmen O, Ugur M, Ekin M, Keles G, Turan C, Oral H. Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme: a prospective randomized placebo controlled study. Eur. J. Obstet. Gynecol. Reprod. Biol.96(2), 187–192 (2001).
   PubMed Web of Science ®Google Scholar
• Graf MA, Fischer R, Naether OG, Baukloh V, Tafel J, Nuckel M. Reduced incidence of ovarian hyperstimulation syndrome by prophylactic infusion of hydroxyaethyl starch solution in an in-vitro fertilization programme. Hum. Reprod.12(12), 2599–2602 (1997).
   PubMed Web of Science ®Google Scholar
• Konig E, Bussen S, Sutterlin M, Steck T. Prophylactic intravenous hydroxyethyle starch solution prevents moderate–severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized, double-blind and placebo-controlled study. Hum. Reprod.13(9), 2421–2424 (1998).
   PubMed Web of Science ®Google Scholar
• Enskog A, Brannstrom M. Immunological aspects of ovarian hyperstimulation syndrome. In: Ovarian Hyperstimulation Syndrome. Gerris J, Delvigne A, Olivennes F (Eds). Informa Healthcare, Oxon, UK, 107–120 (2006).
   Google Scholar
• Tan SL, Balen A, el Hussein E, Campbell S, Jacobs HS. The administration of glucocorticoids for the prevention of ovarian hyperstimulation syndrome in in vitro fertilization: a prospective randomized study. Fertil. Steril.58(2), 378–383 (1992).
   PubMed Web of Science ®Google Scholar
• Lyons CA, Wheeler CA, Frishman GN, Hackett RJ, Seifer DB, Haning RV Jr. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors. Hum. Reprod.9(5), 792–799 (1994).
   PubMed Web of Science ®Google Scholar
• Papanikolaou EG, Tournaye H, Verpoest W et al. Early and late ovarian hyperstimulation syndrome: early pregnancy outcome and profile. Hum. Reprod.20(3), 636–641 (2005).
   PubMed Web of Science ®Google Scholar
• De Neubourg D, Mangelschots K, Van Royen E, Vercruyssen M, Gerris J. Singleton pregnancies are as affected by ovarian hyperstimulation syndrome as twin pregnancies. Fertil. Steril.82(6), 1691–1693 (2004).
   PubMedGoogle Scholar
• D’Angelo A, Amso N. Embryo freezing for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst. Rev.3, CD002806 (2007).
   Google Scholar
• Daya S, Gunby JL. Luteal phase support in assisted reproduction cycles. Cochrane Database Syst. Rev.3, CD004830 (2008).
   Google Scholar
• Abramov Y, Elchalal U, Schenker JG. Pulmonary manifestations of severe ovarian hyperstimulation syndrome: a multicenter study. Fertil. Steril.71(4), 645–651 (1999).
   PubMed Web of Science ®Google Scholar
• Rackow EC, Falk JL, Fein IA et al. Fluid resuscitation in circulatory shock: a comparison of the cardiorespiratory effects of albumin, hetastarch, and saline solutions in patients with hypovolemic and septic shock. Crit. Care Med.11(11), 839–850 (1983).
   PubMed Web of Science ®Google Scholar
• Abramov Y, Fatum M, Abrahamov D, Schenker JG. Hydroxyethylstarch versus human albumin for the treatment of severe ovarian hyperstimulation syndrome: a preliminary report. Fertil. Steril.75(6), 1228–1230 (2001).
   PubMedGoogle Scholar
• Gamzu R, Almog B, Levin Y, Avni A, Lessing JB, Baram A. Efficacy of hydroxyethyl starch and haemaccel for the treatment of severe ovarian hyperstimulation syndrome. Fertil. Steril.77(6), 1302–1303 (2002).
   PubMedGoogle Scholar
• Endo T, Kitajima Y, Hayashi T, Fujii M, Hata H, Azumaguchi A. Low-molecular-weight dextran infusion is more effective for the treatment of hemoconcentration due to severe ovarian hyperstimulation syndrome than human albumin infusion. Fertil. Steril.82(5), 1449–1451 (2004).
   PubMedGoogle Scholar
• Levin I, Almog B, Avni A, Baram A, Lessing JB, Gamzu R. Effect of paracentesis of ascitic fluids on urinary output and blood indices in patients with severe ovarian hyperstimulation syndrome. Fertil. Steril.77(5), 986–988 (2002).
   PubMed Web of Science ®Google Scholar
• Chen CD, Yang JH, Chao KH, Chen SU, Ho HN, Yang YS. Effects of repeated abdominal paracentesis on uterine and intraovarian haemodynamics and pregnancy outcome in severe ovarian hyperstimulation syndrome. Hum. Reprod.13(8), 2077–2081 (1998).
   PubMed Web of Science ®Google Scholar
• Ron-El R, Friedler S, Schachter M, Raziel R. Clinical management, ascites management and obstetrical outcome in patients with ovarian hyperstimulation syndrome. In: Ovarian Hyperstimulation Syndrome. Gerris J, Delvigne A, Olivennes F (Eds). Informa Healthcare, Oxon, UK, 149–158 (2006).
   Google Scholar
• Ozgun MT, Batukan C, Oner G, Uludag S, Aygen EM, Sahin Y. Removal of ascites up to 7.5 liters on one occasion and 45 liters in total may be safe in patients with severe ovarian hyperstimulation syndrome. Gynecol. Endocrinol.24(11), 656–658 (2008).
   PubMed Web of Science ®Google Scholar
• Smith LP, Hacker MR, Alper MM. Patients with severe ovarian hyperstimulation syndrome can be managed safely with aggressive outpatient transvaginal paracentesis. Fertil. Steril. DOI: 10.1016/j.fertnstert.2008.09.011 (2008) (Epub ahead of print).
   Google Scholar
• Csokmay JM, Yauger BJ, Henne MB, Armstrong AY, Queenan JT, Segars JH. Cost analysis model of outpatient management of ovarian hyperstimulation syndrome with paracentesis: ‘tap early and often’ versus hospitalization. Fertil. Steril. DOI: 10.1016/j.fertnstert.2008.09.054 (2008) (Epub ahead of print).
   Google Scholar